Pulse Biosciences (NASDAQ:PLSE) Hits New 12-Month High - Should You Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $23.00 and last traded at $22.85, with a volume of 84098 shares. The stock had previously closed at $20.39.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research note on Thursday, January 2nd.

Pulse Biosciences Trading Down 0.0 %

The business has a 50-day moving average price of $18.86 and a two-hundred day moving average price of $17.95.

Insider Transactions at Pulse Biosciences

In other news, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the transaction, the chief executive officer now directly owns 63,172 shares of the company's stock, valued at $1,100,456.24. This represents a 44.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert W. Duggan purchased 55,256 shares of the company's stock in a transaction dated Friday, December 13th. The shares were purchased at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the transaction, the director now directly owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company's stock.

Hedge Funds Weigh In On Pulse Biosciences

Large investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its stake in Pulse Biosciences by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock worth $2,598,000 after acquiring an additional 1,092 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Pulse Biosciences in the 4th quarter worth about $193,000. Bender Robert & Associates bought a new position in shares of Pulse Biosciences during the 4th quarter valued at about $202,000. Creative Planning raised its holdings in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after buying an additional 11,667 shares in the last quarter. Finally, Oppenheimer & Co. Inc. bought a new stake in Pulse Biosciences in the 4th quarter worth approximately $311,000. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.